1. Home
  2. PTLO vs PRTC Comparison

PTLO vs PRTC Comparison

Compare PTLO & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portillo's Inc.

PTLO

Portillo's Inc.

HOLD

Current Price

$5.51

Market Cap

433.0M

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$17.64

Market Cap

464.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTLO
PRTC
Founded
1963
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.0M
464.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
PTLO
PRTC
Price
$5.51
$17.64
Analyst Decision
Hold
Analyst Count
9
0
Target Price
$8.06
N/A
AVG Volume (30 Days)
1.5M
2.5K
Earning Date
05-28-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.27
N/A
Revenue
$732,066,000.00
N/A
Revenue This Year
$9.71
N/A
Revenue Next Year
$6.20
N/A
P/E Ratio
$19.56
$8.09
Revenue Growth
3.03
N/A
52 Week Low
$4.41
$13.30
52 Week High
$14.47
$20.00

Technical Indicators

Market Signals
Indicator
PTLO
PRTC
Relative Strength Index (RSI) 48.70 40.04
Support Level $5.34 $16.55
Resistance Level $6.12 $18.01
Average True Range (ATR) 0.33 0.30
MACD -0.06 -0.18
Stochastic Oscillator 36.27 0.00

Price Performance

Historical Comparison
PTLO
PRTC

About PTLO Portillo's Inc.

Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: